Menus Subscribe Search

Follow us


Defeating Bacteria From the Inside Out

• April 19, 2012 • 4:03 PM

The world’s most ubiquitous organism could save millions of lives — if only they could get a new tryout.

Bacteriophages, a class of viruses that only attack bacteria, have been controversial ever since their discovery by a brash, young, self-taught researcher named Felix d’Herelle nearly a century ago.

In the 1920s and ’30s, before the advent of antibiotics, doctors using phage therapy reported near miraculous cures for infections, even at the critical stage. The treatments, however, didn’t work in every case, and after the discovery of much more reliable antibiotics, starting with penicillin in the 1940s, phage therapy was ushered off the medical stage in the United States and Western Europe.

Anna Kuchment, an editor at Scientific American, labeled phage therapy The Forgotten Cure in her recent book, in which she says the practice took up residence behind the Iron Curtain where antibiotics were scarce.

Alexander Sulakvelidze, who grew up in Tbilisi, Georgia, says phage therapy was there for him when he was a child. “Everybody took them when they got sick. It was just something you did.”

Although we now take penicillin and its host of antibiotic descendants for granted, scientists say with the emergence of more strains of antibiotic-resistant disease, it may be just a matter of time before we are forced to seek some alternatives, and researchers suggest that phage therapy may be just the ticket. And since the end of the Cold War, word has been trickling out that phage therapy still works.

• • • • • • • • • • • • • • •

Forty times smaller than the bacteria they prey upon, each species of phage hones in on one specific type of bacteria. Finding its target, a phage attaches to its bacterial host and deliver a dose of DNA that converts the bacteria into a factory to make more phages — eating the germ from the inside out.

Phages can be found almost anywhere there is water (including the human nostril); they may be the most common organism on Earth. Mankind is awash in them, says Sulakvelidze, who grew up to be chief science officer for Intralytix, a Baltimore-based manufacturer of phage-based products.

For an effective therapy, proponents note, caregivers need to identify a pathogen precisely, then pick the exact species of phage that attacks it. (Antibiotics can work without knowing the specific bacterium because they attack a broad spectrum of bacteria.) The ability to identify the offending bacteria, although not foolproof, is much improved by genetic analysis and other means not available during 1930s.

Still, well-understood bacterial diseases like shigella, a disease of the digestive tract, make a good starting point for deploying phages. If phage therapy were more widely available, Sulakvelidze said, “and you saved just 10 percent of the 700,000 children killed each year by shigella, it would be mind boggling.”

And while they’re fast acting, beginning the process of breaking down targeted bacteria within minutes of application, when phages are done destroying bacteria they become inactive, he adds.

“There would be no downside to trying [phage therapy],” he argues, “The worst-case scenario would be that it did not work — it’s pretty well established that it could do no harm.”

(Because bacteria can be cagey opponents, Sulakvelidze says it would be best to use a variety of species of phage in a cocktail, to be sure to eliminate both the target strain and any closely related variants that might arise during an infection.)

Too good to be true? In a way.

Phage therapy is not a panacea, Sulakvelidze says. “Baseless claims” made by early enthusiasts helped to diminish phage therapy’s reputation in the past.

For instance, he contrasts shigella with tuberculosis, for which it’s “difficult to imagine” a phage-based treatment. That’s in part because the phage cannot get inside of human cells where TB takes up residence, nor can they easily pursue the TB bacterium to the various parts of the body where it hides out.

• • • • • • • • • • • • • • •

The road to market is not an easy one, and experts say for a new antibiotic getting through the administrative hurdles can take years and cost in the neighborhood of $100 million, with the essential requirement of the double-blind clinical trial.

Dr. Glenn Morris, director of the Emerging Pathogens Institute at the University of Florida, co-founded Intralytix, Inc., with Sulakvelidze. While subsequent applications have gone more smoothly, he said, the U.S. Food and Drug Administration approval process for ListShield, the firm’s first phage-based product targeting listeria in food, took four years to reach the approval stage. Morris says that was “largely because there was no standard channel at the FDA for considering phage-based products.”

Phage preparations, by their nature need to be individualized in order to perform at their best. Ideally, Sulakvelidze says, an appropriate regulatory process would take a non-traditional approach, granting manufacturers the flexibility to mix and match phage combinations to address distinct outbreaks, or individual cases, without having to re-enact the entire clinical trial procedure every time they target a phage against a different bacterium.

Bill Egan, the former acting director of the FDA Office of Vaccine Research and Review, says he can see some logic in that approach. He envisions a process similar to the one used for approving annual influenza vaccines, which allows manufacturers to obtain approval based for new versions of influenza vaccines without the necessity for repeated large-scale clinical trials.

He says after first demonstrating that phage therapy can be performed with safety and efficacy, manufacturers of phage treatments would then need to be able to show they “have a procedure in place to handle the individual outbreak, that they have a way to determine the efficacy of therapy.” And finally they would need to demonstrate that when they put a phage preparation together “that it is effective.”

Although the FDA approval process can be arduous, Egan says, it’s flexible. The agency, “as much as anybody else, wants to see safe and effective products go out on the market.”

Ultimately, Egan says the test of phage therapy will be public acceptance. “The physicians will have their set criteria and patients will have theirs. That happens with any new thing, this happened when generics were first introduced; there was a lot of resistance. Now everybody takes them.”

David Richardson
David Richardson began his journalism career operating a video news service in Washington, D.C., that covered federal agencies and Congress. His film production work has since ranged from postings at the White House to rural villages of Botswana, documenting community-centered HIV prevention programs. He holds a B.A. degree in government from Dartmouth College. He now writes on science, the environment and policy from Baltimore, Md., where he's had some success growing organic produce in a small backyard garden.

More From David Richardson

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

November 21 • 4:00 PM

Why Are America’s Poorest Toddlers Being Over-Prescribed ADHD Drugs?

Against all medical guidelines, children who are two and three years old are getting diagnosed with ADHD and treated with Adderall and other stimulants. It may be shocking, but it’s perfectly legal.



November 21 • 2:00 PM

The Best Moms Let Mess Happen

That’s the message of a Bounty commercial that reminds this sociologist of Sharon Hays’ work on “the ideology of intensive motherhood.”


November 21 • 12:00 PM

Eating Disorders Are Not Just for Women

Men, like women, are affected by our cultural preoccupation with thinness. And refusing to recognize that only makes things worse.


November 21 • 10:00 AM

Queens of the South

Inside Asheville, North Carolina’s 7th annual Miss Gay Latina pageant.


November 21 • 9:12 AM

‘Shirtstorm’ and Sexism in Science

Following the recent T-shirt controversy, it’s clear that sexism in science persists. But the forces driving the gender gap are still being debated.


November 21 • 8:00 AM

What Makes a Film Successful in 2014?

Domestic box office earnings are no longer a reliable metric.



November 21 • 6:00 AM

What Makes a City Unhappy?

According to the National Bureau of Economic Research, Dana McMahan splits time between two of the country’s unhappiest cities. She set out to explore the causes of the happiness deficits.


November 21 • 5:04 AM

Sufferers of Social Anxiety Disorder, Your Friends Like You

The first study of friends’ perceptions suggest they know something’s off with their pals but like them just the same.


November 21 • 4:00 AM

In 2001 Study, Black Celebrities Judged Harshly in Rape Cases

When accused of rape, black celebrities were viewed more negatively than non-celebrities. The opposite was true of whites.


November 20 • 4:00 PM

Women, Kink, and Sex Addiction: It’s Not Like the Movies

The popular view is that if a woman is into BDSM she’s probably a sex addict, and vice versa. In fact, most kinky women are perfectly happy—and possibly healthier than their vanilla counterparts.


November 20 • 2:00 PM

A Majority of Middle-Class Black Children Will Be Poorer as Adults

The disturbing findings of a new study.


November 20 • 12:00 PM

Standing Up for My Group by Kicking Yours

Members of a minority ethnic group are less likely to express support for gay equality if they believe their own group suffers from discrimination.


November 20 • 10:00 AM

For Juvenile Records, It’s ‘Justice by Geography’

A new study finds an inconsistent patchwork of policies across states for how juvenile records are sealed and expunged.


November 20 • 8:00 AM

Surviving the Secret Childhood Trauma of a Parent’s Drug Addiction

As a young girl, Alana Levinson struggled with the shame of her father’s substance abuse. But when she looked more deeply into the research on children of drug-addicted parents, she realized society’s “conspiracy of silence” was keeping her—and possibly millions of others—from adequately dealing with the experience.



November 20 • 6:00 AM

Extreme Weather, Caused by Climate Change, Is Here. Can Nike Prepare You?

Following the approach we often see from companies marketing products before big storms, Nike focuses on climate change science in the promotion of its latest line of base-layer apparel. Is it a sign that more Americans are taking climate change seriously? Don’t get your hopes up.


November 20 • 5:00 AM

How Old Brains Learn New Tricks

A new study shows that the neural plasticity needed for learning doesn’t vanish as we age—it just moves.


November 20 • 4:00 AM

The FBI’s Dangerous Misrepresentation of Encryption Law

The FBI no more deserves a direct line to your data than it deserves to intercept your mail at the post office. But it doesn’t want you to know that.


November 20 • 2:00 AM

Brain Drain Is Economic Development

It may be hard to see unless you shift your focus from places to people, but both destination and source can benefit from “brain drain.”


November 19 • 9:00 PM

Gays Rights Are Great, but Ixnay on the PDAs

New research suggests both heterosexuals and gay men are uncomfortable with public same-sex kissing.


November 19 • 4:00 PM

The Red Cross’ Own Employees Doubt the Charity’s Ethics

Survey results obtained by ProPublica also show a crisis of trust in the charity’s senior leadership.



November 19 • 2:00 PM

Egg Freezing Isn’t the Feminist Issue You Think It Is

New benefits being offered by Apple and Facebook probably aren’t about discouraging women from becoming mothers at a “natural” age.


Follow us


Sufferers of Social Anxiety Disorder, Your Friends Like You

The first study of friends' perceptions suggest they know something's off with their pals but like them just the same.

Standing Up for My Group by Kicking Yours

Members of a minority ethnic group are less likely to express support for gay equality if they believe their own group suffers from discrimination.

How Old Brains Learn New Tricks

A new study shows that the neural plasticity needed for learning doesn't vanish as we age—it just moves.

Ethnic Diversity Deflates Market Bubbles

But it's not in the rainbow and sing-along way you'd hope for. We just don't trust outsiders' judgments.

Online Brain Exercises Are Probably Useless

Even under the guidance of a specialist trainer, computer-based brain exercises have only modest benefits, a new analysis shows.

The Big One

One company, Comcast, will control up to 40 percent of Internet service coverage in the U.S., and 19 of the top 20 cable markets, if a proposed merger with Time Warner Cable is approved by regulators. November/December 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.